Search

This retrospective study aimed to evaluate factors associated with survival and to compare characteristics between tumour localizations in dogs with urinary transitional cell carcinoma (TCC) that underwent whole-body computed tomography (CT) at diagnosis. Dogs with histologically confirmed TCC that received medical therapy between 2010 and 2017 were included; dogs that underwent surgery or radiotherapy for the primary tumour were excluded. According to the CT findings, primary tumour localization (classified into the Bladder, Urethra and Bladder and Urethra groups), prostate involvement, iliosacral lymphadenomegaly, sternal lymphadenomegaly and metastasis to the bone and lung were evaluated for survival analysis. CT at diagnosis revealed iliosacral lymphadenomegaly, sternal lymphadenomegaly, bone metastasis and lung metastasis in 47.7%, 18.5%, 24.6% and 35.4% of the 65 included dogs, respectively. The overall median survival time was 196 days. On multivariable analysis, TCC localization (hazard ratio [HR], 1.90; P = .037), bone metastasis (HR, 2.76; P = .013) and sternal lymphadenomegaly (HR, 3.56; P = .004) were significantly associated with survival. Compared to the Bladder group (n = 16), the Urethra group (n = 26) had higher metastasis rates to the bone (6.3% vs 42.3%; P = .045) and lung (6.3% vs 46.2%; P = .022). The survival time was shorter in the Urethra group than in the Bladder group (121.5 vs 420 days; P < .001), and it was similar only in female dogs (247 vs 420 days; P = .031). These findings suggest that whole-body CT could be valuable for predicting the prognosis in urinary TCC.

Little evidence is available regarding the prognosis of dogs with malignant ovarian tumours. The objective of this retrospective study was to describe the outcomes and determine the prognostic factors for dogs with malignant ovarian tumours following treatment, including surgery with or without adjuvant therapy. Eighteen dogs were studied, their median age was 12 years (range: 7-15 years), and their median body weight was 6.9 kg (range: 2.3-17.8 kg). Following histopathologic diagnoses revealed that granulosa cell tumour was the most common type (n = 9), followed by dysgerminoma (n = 5), and adenocarcinoma (n = 4). Eleven dogs had surgery alone. Seven dogs had surgery with adjuvant therapy, including chemotherapy and/or radiotherapy. The median survival time (ST) was 1009 days when only deaths owing to the ovarian tumours were considered, and predictors of median ST were T-category (≥ T3, 443 days vs ≤ T2, 1474 days; P = .002), presence of metastatic disease (present, 391 days vs absent, 1474 days; P < .001) and lymphovascular space invasion (present, 428 days vs absent, 1474 days; P = .003) in a univariate analysis. Median ST in dogs with granulosa cell tumour seemed longer than in dogs with dysgerminoma and adenocarcinoma, although the difference was statistically insignificant (1474 days vs 458 days, respectively; P = .10). Considering the good prognosis, aggressive treatment can be recommended for dogs with malignant ovarian tumours, especially early-stage cases. Despite metastasis being present at diagnosis, half of the dogs with metastasis survived for more than 1 year.

Thymomas are one of the most common tumors of the cranial mediastinum in dogs; however there is limited information available on the use of radiation therapy for treating this neoplasm. Objectives of the current retrospective observational study were to describe outcomes and side effects of a hypofractionated radiation therapy protocol in a group of dogs with confirmed thymoma. A total of eight dogs were included. To generate individualized treatment plans, we designed the planning target volume according to the limits on mean lung dose and the percentage of the total lung volume exceeding 20 Gy (V20). The total administered dose was 48-49 Gy, with one fraction per week for a total of six to seven fractions. After therapy, two dogs achieved complete responses, two achieved partial responses, and the disease remained stable in two. Two dogs died during the radiation therapy protocol and were not classified. The median mean lung dose and V20 were 6.0 Gy (range: 3.1-15.0 Gy) and 12.4% (range: 2.3-27.5%), respectively. The overall response rate was 50.0%, and the median time to response following treatment initiation was 22 days (range: 14-115 days). Acute and late side effects were common in the skin and/or lung and were self-limiting or asymptomatic. The median survival time was not reached (range: 8-1128 days) and the 1 year survival rate was 75.0%. Hypofractionated radiation therapy was well tolerated in this sample of dogs with thymoma and may be considered when owners decline surgical treatment or the tumor is deemed unresectable.

This study was conducted to assess the usefulness of thermography for quantifying facial temperature before and after orthognathic surgery and intermaxillary fixation, and the effects of these orthognathic procedures on facial temperature. Facial thermograms of 10 patients who underwent bilateral sagittal split ramus osteotomy (SSRO, one-jaw group) and another 10 patients who underwent Le Fort I osteotomy and bilateral SSRO (two-jaw group) were taken 1 day before orthognathic surgery (T1) and at release of intermaxillary fixation 7 days later (T2). Two thermograms taken 30 s (TG1) and 3 min (TG2) after the start of recording at T1 and T2 were used. A square (26 × 26 pixels) was marked on each thermogram and the mean facial temperature for each square was measured. Three-way analysis of variance was used for statistical comparisons. Facial temperatures were significantly higher at T2 than at T1 on TG1 and TG2, and were significantly higher on TG2 than on TG1 at T1 and T2. The two-jaw group had a significantly higher facial temperature than the one-jaw group. Thermography was useful for quantitative assessment of facial temperature in patients undergoing orthognathic surgery. Changes in facial temperature were due predominantly to inflammation after surgery, rather than to sarcopenia.

To assess the effect of the contact compressive force to seat orthodontic brackets on shear bond strength (SBS) and adhesive thickness using adhesive resins with different viscosities. A total of 184 premolars were divided equally into eight groups of 23. Transbond XT and Beauty Ortho Bond paste viscous self-etching adhesive systems were used with contact compressive forces of 0.5, 1, 2, and 3 N (groups 1–4 and groups 5–8, respectively) via a push–pull tension gauge. SBS and adhesive thickness were measured in each adhesive system for each contact compressive force. Significant differences existed in the SBSs between the adhesive systems for each contact compressive force and the SBSs were significantly higher in groups 1 (17 MPa) and 2 (16 MPa) than in groups 3 (14 MPa) and 4 (13 MPa). Significant differences existed for the adhesive thickness between the adhesive systems for the three contact compressive forces less than 3 N. The adhesive in group 1 (0.184 mm) was significantly thicker than that in groups 2–4 (from 0.098 to 0.129 mm). In groups 2 (0.129 mm) and 3 (0.121 mm) it was thicker than in group 4 (0.098 mm), and in group 5 (0.119 mm) it was thicker than in groups 6–8 (from 0.087 to 0.088 mm). The high-viscosity adhesive Transbond XT exhibited higher SBSs than the low-viscosity Beauty Ortho Bond paste. For the adhesive Transbond XT, lower contact compressive forces produced greater adhesive thicknesses and higher SBSs. For the Beauty Ortho Bond paste, no significant changes in the adhesive thickness or SBS values were observed for contact compressive forces greater than 0.5 N.